- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Schuster discusses how radiotracers will be used to treat prostate cancer in the future
“I think that we keep getting better and better tools…[and] I think understanding how to utilize these tools will be a challenge in the future,” says David M. Schuster, MD, FACR.
In this video, David M. Schuster, MD, FACR, discusses the takeaways and further research associated with the study, “Detection rates of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT),” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Schuster is a professor of urology and radiology and imaging sciences, a GRA distinguished cancer scientist, and the director of the division of nuclear medicine and molecular imaging at the Emory University School of Medicine in Atlanta, Georgia.
![[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Furologytimes%2F6583419a0719128d5ec70eb6a2f5729faf857b50-1200x905.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer")
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Approval sought for TLX007-CDx in prostate cancer
May 28th 2024“If approved by the FDA, this new product will have a significant impact on prostate cancer patients, physicians, and their caregivers by helping to eliminate the inequity of access to PSMA-PET agents, and increase the ability to accurately diagnose cancer early, reducing the cost of care, and increasing the probability of patients’ survival," says Mike Crosby.
